[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] # Veracyte, Inc. (VCYT) Veracyte's stock shows mixed signals with increased social media buzz around its diagnostic tools, yet faces headwinds from negative market sentiment and a recent downgrade, keeping its price near a 52-week low. ### About Veracyte, Inc. Veracyte, Inc. is a healthcare company specializing in AI-driven diagnostics. Veracyte, Inc. uses the ticker $VCYT for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors. ### Insights - Veracyte, Inc. (VCYT) trading volume is up XXXXXX% from the previous week. - Veracyte, Inc. (VCYT) social dominance is up XXXXX% from the previous X months. - Veracyte, Inc. (VCYT) posts created is up XXX% from the previous week. ### Price: $XXXXX  [Price 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/close.tsv) The stock price is near its 52-week high, supported by positive social media engagement and recent research developments, though it faces headwinds from negative market sentiment and a prior downgrade. 24-Hour: -XXXX% 7-Day: XXXX% 30-Day: XXXXX% 1-Year High: $XXXXX on 2025-11-25 1-Year Low: $XX on 2025-07-21 ### AltRank: XXXXX  [AltRank 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/alt_rank.tsv) Veracyte, Inc. (VCYT) is currently AltRank #1,686 based on combined combined social and market metrics Daily Average: XXXXX X Week: XXXXX +564 X Month: XXXXX +390 X Months: XXXXX -XXX X Year: XXXXX +794 1-Year High: XXXXX on 2025-09-24 1-Year Low: XX on 2025-03-08 ### Galaxy Score: XXXXX  [Galaxy Score 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/galaxy_score.tsv) Current Value: XXXXX Daily Average: XX X Week: XX -XX X Month: XX -XX X Months: XX -XX X Year: XX -XX 1-Year High: XX on 2025-11-05 1-Year Low: X on 2025-12-09 ### Engagements: XXX (24h)  [Engagements 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/interactions.tsv) Current Value: XXX Daily Average: XXXXX X Week: XXXXX -XX% X Month: XXXXXX -XXXX% X Months: XXXXXXX +22% X Year: XXXXXXX +37% 1-Year High: XXXXXX on 2025-07-11 1-Year Low: X on 2025-10-12 Engagements by network (24h): Reddit: X TikTok: XX X: XXX YouTube: XX ### Mentions: XX (24h)  [Mentions 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/posts_active.tsv) Current Value: XX Daily Average: XX X Week: XX -XX% X Month: XXX +78% X Months: XXXXX +83% X Year: XXXXX +118% 1-Year High: XXX on 2025-06-28 1-Year Low: X on 2025-10-12 Mentions by network (24h): Reddit: X TikTok: X X: XX YouTube: X ### Creators: XX (24h)  [Creators 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning Veracyte, Inc. (VCYT) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX X Week: XX -XX% X Month: XXX +65% X Months: XXXXX +226% X Year: XXXXX +202% 1-Year High: XXX on 2025-06-28 1-Year Low: X on 2025-10-12 The most influential creators that mention Veracyte, Inc. in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@linhnguyen64143](/creator/twitter/linhnguyen64143) | X | XX | X | X | [View More](/list/creators/$vcyt/100) ### Sentiment: XXX%  [Sentiment 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/sentiment.tsv) Current Value: XXX% Daily Average: XX% X Week: XXX% no change X Month: XXX% no change X Months: XXX% no change X Year: XXX% +25% 1-Year High: XXX% on 2025-01-15 1-Year Low: XX% on 2025-03-14 Most Supportive Themes: - Afirma GRID Research Tool: (30%) Veracyte's new Afirma GRID research tool is being highlighted for its potential to advance thyroid nodule testing. - Prostate Cancer Biomarker Research: (25%) Veracyte is involved in groundbreaking research using the Decipher GRID-enabled biomarker PAM50 to predict hormone therapy benefit in prostate cancer. - Affordable Growth Selection: (15%) Veracyte is identified as a top affordable growth stock by ChartMill, indicating positive investor interest. Most Critical Themes: - Negative Market Sentiment and Downgrade: (70%) Despite increased social engagement, Veracyte's stock price is near its 52-week low due to negative market sentiment and a recent downgrade. ### Social Dominance: XXXXXXX%  [Social Dominance 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/social_dominance.tsv) Current Value: XXXXXXX% Daily Average: XXXXXXX% X Week: XXXXXX% +0.0035% X Month: XXXXXX% +0.0013% X Months: XXXXXX% +0.0004000000000000002% X Year: XXXXXX% -XXXXXX% 1-Year High: XXXX% on 2025-01-02 1-Year Low: XXXXXX% on 2025-10-12 ### Market Dominance: XXXXXXX%  [Market Dominance 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/market_dominance.tsv) Current Value: XXXXXXX% Daily Average: X% 1-Year High: XXXXX% on 2025-11-25 1-Year Low: XXXXXXX% on 2025-03-10 ### Market Cap: $XXXXXXXXXXXXX  [Market Cap 24-Hour Time-Series Raw Data](/topic/$vcyt/time-series/market_cap.tsv) Current Value: $XXXXXXXXXXXXX Daily Average: $XXXXXXXXXXXXX X Week: $XXXXXXXXXXXXX -$6.90% X Month: $XXXXXXXXXXXXX +$5.10% X Months: $XXXXXXXXXXXXX +$66% X Year: $XXXXXXXXXXXXX +$4.60% 1-Year High: $XXXXXXXXXXXXX on 2025-11-25 1-Year Low: $XXXXXXXXXXXXX on 2025-07-21 ### Top Veracyte, Inc. Social Posts Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "As we gather in San Antonio this week for #SABCS25 we're reminded of the importance of precision medicine in breast cancer care. We look forward to connecting with oncologists researchers and colleagues because when we get together breast cancer diagnostics get ahead. The Challenge Globally breast cancer remains the most common cancer among women with over XXX million new cases reported in 2022. In the US alone an estimated 319750 people will be diagnosed with invasive breast cancer in 2025 with about XX% - more than 225000 - expected to have hormone receptor-positive breast cancer. Our" [X Link](https://x.com/Veracyte/status/1998052448506978428) [@Veracyte](/creator/x/Veracyte) 2025-12-08T15:30Z 1218 followers, XXX engagements "Pre-Market Midcaps ($2-20B) - Dec X Gainers Losers $WVE +68% $FLNC -XXX% $KYMR +34% $LCID -XXX% $GPCR +31% $CHA -XXX% $CFLT +29% $PBF -XXX% $NRIX +16% $TTAM -XXX% $OCUL +15% $VCYT -XXX% $ARWR +12% $ESTA -XXX% $COGT +11% $LIF -XXX% $RARE +8.3% $UGP -XXX% $PRIM +8.1% $WSHP -XXX% $INDV +8% $CRK -XXX% $ACLX +7.3% $ENTG -XXX% $DYN +6.3% $IFF -X% $RXRX +5.7% $RRC -X% $TERN +5.6% $ENLT -2%" [X Link](https://x.com/MarketCap_Live/status/1998044066718879977) [@MarketCap_Live](/creator/x/MarketCap_Live) 2025-12-08T14:56Z XXX followers, XXX engagements "Pre-Market Movers December X Top Gainers (Pre-Market) $KYMR Kymera Therapeutics +39.9% $GPCR Structure Therapeutics +30.2% $CFLT Confluent +29.4% $OCUL Ocular Therapeutix +18.0% $ACLX Arcellx +12.1% Top Losers (Pre-Market) $MRVL Marvell Technology -XXX% $UL Unilever -XXX% $VCYT Veracyte -XXX% $MEOH Methanex -XXX% $CRVW CoreWeave -4.6%" [X Link](https://x.com/allday_stocks/status/1998032506008805623) [@allday_stocks](/creator/x/allday_stocks) 2025-12-08T14:10Z 2305 followers, XXX engagements "Artisan US Mid Cap Growth Strategy on Veracyte $VCYT US Thesis: Veracyte is a molecular diagnostics company that enables noninvasive cancer testing leading to significant revenue growth and expansion of its product offerings. (From their Q325 letter link in bio)" [X Link](https://x.com/StockCompil/status/1997403267924386075) [@StockCompil](/creator/x/StockCompil) 2025-12-06T20:30Z 9353 followers, 1173 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Veracyte's stock shows mixed signals with increased social media buzz around its diagnostic tools, yet faces headwinds from negative market sentiment and a recent downgrade, keeping its price near a 52-week low.
Veracyte, Inc. is a healthcare company specializing in AI-driven diagnostics.
Veracyte, Inc. uses the ticker $VCYT for trading. Listed in the Stocks category within the Healthcare sectors.
Price 24-Hour Time-Series Raw Data
The stock price is near its 52-week high, supported by positive social media engagement and recent research developments, though it faces headwinds from negative market sentiment and a prior downgrade.
24-Hour: -XXXX% 7-Day: XXXX% 30-Day: XXXXX%
1-Year High: $XXXXX on 2025-11-25
1-Year Low: $XX on 2025-07-21
AltRank 24-Hour Time-Series Raw Data
Veracyte, Inc. (VCYT) is currently AltRank #1,686 based on combined combined social and market metrics
Daily Average: XXXXX
X Week: XXXXX +564
X Month: XXXXX +390
X Months: XXXXX -XXX
X Year: XXXXX +794
1-Year High: XXXXX on 2025-09-24
1-Year Low: XX on 2025-03-08
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -XX
X Month: XX -XX
X Months: XX -XX
X Year: XX -XX
1-Year High: XX on 2025-11-05
1-Year Low: X on 2025-12-09
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
X Week: XXXXX -XX%
X Month: XXXXXX -XXXX%
X Months: XXXXXXX +22%
X Year: XXXXXXX +37%
1-Year High: XXXXXX on 2025-07-11
1-Year Low: X on 2025-10-12
Engagements by network (24h): Reddit: X TikTok: XX X: XXX YouTube: XX
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XX -XX%
X Month: XXX +78%
X Months: XXXXX +83%
X Year: XXXXX +118%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-10-12
Mentions by network (24h): Reddit: X TikTok: X X: XX YouTube: X
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Veracyte, Inc. (VCYT) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX -XX%
X Month: XXX +65%
X Months: XXXXX +226%
X Year: XXXXX +202%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-10-12
The most influential creators that mention Veracyte, Inc. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @linhnguyen64143 | X | XX | X | X |
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XXX% no change
X Month: XXX% no change
X Months: XXX% no change
X Year: XXX% +25%
1-Year High: XXX% on 2025-01-15
1-Year Low: XX% on 2025-03-14
Most Supportive Themes:
Most Critical Themes:
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXXXX%
X Week: XXXXXX% +0.0035%
X Month: XXXXXX% +0.0013%
X Months: XXXXXX% +0.0004000000000000002%
X Year: XXXXXX% -XXXXXX%
1-Year High: XXXX% on 2025-01-02
1-Year Low: XXXXXX% on 2025-10-12
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-11-25
1-Year Low: XXXXXXX% on 2025-03-10
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$6.90%
X Month: $XXXXXXXXXXXXX +$5.10%
X Months: $XXXXXXXXXXXXX +$66%
X Year: $XXXXXXXXXXXXX +$4.60%
1-Year High: $XXXXXXXXXXXXX on 2025-11-25
1-Year Low: $XXXXXXXXXXXXX on 2025-07-21
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"As we gather in San Antonio this week for #SABCS25 we're reminded of the importance of precision medicine in breast cancer care. We look forward to connecting with oncologists researchers and colleagues because when we get together breast cancer diagnostics get ahead. The Challenge Globally breast cancer remains the most common cancer among women with over XXX million new cases reported in 2022. In the US alone an estimated 319750 people will be diagnosed with invasive breast cancer in 2025 with about XX% - more than 225000 - expected to have hormone receptor-positive breast cancer. Our"
X Link @Veracyte 2025-12-08T15:30Z 1218 followers, XXX engagements
"Pre-Market Midcaps ($2-20B) - Dec X Gainers Losers $WVE +68% $FLNC -XXX% $KYMR +34% $LCID -XXX% $GPCR +31% $CHA -XXX% $CFLT +29% $PBF -XXX% $NRIX +16% $TTAM -XXX% $OCUL +15% $VCYT -XXX% $ARWR +12% $ESTA -XXX% $COGT +11% $LIF -XXX% $RARE +8.3% $UGP -XXX% $PRIM +8.1% $WSHP -XXX% $INDV +8% $CRK -XXX% $ACLX +7.3% $ENTG -XXX% $DYN +6.3% $IFF -X% $RXRX +5.7% $RRC -X% $TERN +5.6% $ENLT -2%"
X Link @MarketCap_Live 2025-12-08T14:56Z XXX followers, XXX engagements
"Pre-Market Movers December X Top Gainers (Pre-Market) $KYMR Kymera Therapeutics +39.9% $GPCR Structure Therapeutics +30.2% $CFLT Confluent +29.4% $OCUL Ocular Therapeutix +18.0% $ACLX Arcellx +12.1% Top Losers (Pre-Market) $MRVL Marvell Technology -XXX% $UL Unilever -XXX% $VCYT Veracyte -XXX% $MEOH Methanex -XXX% $CRVW CoreWeave -4.6%"
X Link @allday_stocks 2025-12-08T14:10Z 2305 followers, XXX engagements
"Artisan US Mid Cap Growth Strategy on Veracyte $VCYT US Thesis: Veracyte is a molecular diagnostics company that enables noninvasive cancer testing leading to significant revenue growth and expansion of its product offerings. (From their Q325 letter link in bio)"
X Link @StockCompil 2025-12-06T20:30Z 9353 followers, 1173 engagements
/topic/$vcyt